Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

  • End date
    Oct 10, 2024
  • participants needed
  • sponsor
    3D Medicines (Sichuan) Co., Ltd.
Updated on 10 July 2022


This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

Condition Advanced Endometrial Cancer
Treatment Envafolimab, Envafolimab+Lenvatinib
Clinical Study IdentifierNCT05112991
Sponsor3D Medicines (Sichuan) Co., Ltd.
Last Modified on10 July 2022


Yes No Not Sure

Inclusion Criteria

Volunteer to participate and sign the informed consent form
Has a histologically confirmed diagnosis of endometrial carcinoma (EC). Has Documented evidence of advanced, recurrent or metastatic EC and are not candidates for curative surgery or radiation
Failure or intolerance of standard first-line platinum-based chemotherapy regimen for EC
Note: If recurrence occurs during adjuvant/neoadjuvant therapy or within 12
months after completion, adjuvant/neoadjuvant therapy is considered to be the
first-line treatment for advanced disease. There is no restriction regarding
prior hormonal therapy
Has at least 1 measurable target lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and confirmed by Blind Independent Imaging Review Committee (BIRC)
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of 12 weeks or more
Sufficient organ and bone marrow function (no hematopoietic growth factor, blood transfusion or platelet therapy was given within 14 days before the first study drug treatment)
Archival tumor tissue or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis. Tissue samples need to be from lesions that have not received local radiotherapy
Females of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of study drug

Exclusion Criteria

Previous lab results showed dMMR or MSI-H
Participate in the clinical trials of other investigational drugs within 28 days before the first medication; or have received anti-tumor treatment within 2 weeks, including but not limited to chemotherapy and radiotherapy or targeted therapy
The toxicity of previous anti-tumor treatments has not recovered to 0 or 1 level
Recieved major surgery with 28 days before the first medication or has serious nonhealing wound, ulcer, or bone fracture at screening
Has received prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Uncontrolled blood pressure (BP) with or without antihypertensive medications, defined as BP >150/90 mmHg
Uncontrolled or major Cardio-cerebral vascular disease
Have active, or have had autoimmune diseases or risks that may recur. However, subjects required only replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) or with skin diseases that do not require systemic treatmentare are allowed to be included
Subjects who need to use corticosteroids (> 10 mg/day prednisone equivalent dose) for systemic therapy within 14 days before the study drug is administered
Has received a live-virus vaccination within 28 days of planned treatment start or plan to reveived a live-virus vaccination during the study
Has current or suspected (non-infectious) pneumonitis
Active infection (any infection requiring systemic treatment)
Has active Hepatitis B or C
Is positive for Human Immunodeficiency Virus (HIV)
Has uncontrolled pericardial effusion, pleural effusion or ascites
Has symptomatic/active brain metastasis or meningeal carcinomatosis; for patients with brain metastases who have previously received treatment, if the clinical and imaging evidence does not indicate disease progression within 4 weeks before the first study drug treatment, and 2 weeks before the first administration There is no need to receive corticosteroid treatment and can be considered for inclusion
Suffered from other known malignant tumors within 5 years before enrollment (except for treated skin basal cell carcinoma, skin squamous cell carcinoma and/or carcinoma in situ after radical resection)
Hypersensitivity to either of the study drug or its components
Females who are pregnant or breastfeeding and who refuse to use a highly effective method of contraception throughout the entire study period, and for 6 months after the last dose of study drug
According to the judgement of the investigators, there are other factors indicate that the subject should not be enrolled
Has received prior treatment with any treatment targeting VEGF-directed angiogenesis
Has radiographic evidence of major blood vessel invasion/infiltration
Has a history of hypertensive crisis or hypertensive encephalopathy
Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Has a history of serious bleeding disease within 6 months prior to the first dose of study drug
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note